| 产品描述: | Seclidemstat (SP-2577) mesylate is a potent noncompetitive and reversible KDM1A (LSD1) inhibitor (Ki=31 nM, IC50=13 nM). Seclidemstat mesylate promotes antitumor immunity in switch/sucrose nonfermentable (SWI/SNF) complex mutated ovarian cancer, as well as inhibit virus production, viral DNA replication, and late gene expression. Seclidemstat mesylate can be used for the research of Ewing Sarcoma. |
| 靶点: |
KDM1/LSD1 |
| 体内研究: |
Seclidemstat (72 小时) mesylate 可抑制 SWI/SNF 突变依赖性肿瘤细胞增殖,IC50 范围为 0.013 至 2.819 μM (COV434、BIN67、SCCOHT-1、TOV21G、SKOV3、A427、H522、A549、H1299、G401、G402、HCC15 细胞)。 Seclidemstat (72 小时)mesylate 可促进 SCCOHT 细胞系(SCCOHT-1、BIN67 和 COV434 细胞)中内源性逆转录病毒 (ERV) 的表达和 IFNβ 通路的激活。 Seclidemstat (3 μM) mesylate 可促进 SCCOHT COV 434 pIND 20 中的 PD-L1 表达BRG1-2.7 细胞系。 |
| 参考文献: |
1. Dai XJ, et al. Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1 [published correction appears in J Med Chem. 2021 May 13;64(9):6410-6411]. J Med Chem. 2021;64(5):2466-2488. 2. Soldi R, et al. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer. PLoS One. 2020;15(7):e0235705. Published 2020 Jul 10. |
| 保存条件: |
-80°C 12个月; -20°C 6个月,干燥, 避光 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.828 ml |
9.14 ml |
18.28 ml |
| 5 mM |
0.366 ml |
1.828 ml |
3.656 ml |
| 10 mM |
0.183 ml |
0.914 ml |
1.828 ml |
| 50 mM |
0.037 ml |
0.183 ml |
0.366 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |